PubRank

Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma

Clinical Trial ID NCT00683670

PubWeight™ 12.32‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00683670

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cancer statistics, 2005. CA Cancer J Clin 2005 25.65
2 A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991 14.57
3 Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998 11.03
4 High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999 10.86
5 Dendritic cells: specialized and regulated antigen processing machines. Cell 2001 10.44
6 Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998 7.48
7 Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999 5.95
8 Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005 5.43
9 Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2004 5.02
10 Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995 4.31
11 Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015 4.29
12 Dendritic cell immunotherapy: mapping the way. Nat Med 2004 4.28
13 Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999 4.20
14 Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994 3.96
15 Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994 3.94
16 Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004 3.46
17 Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999 3.33
18 Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001 3.01
19 Sensing pathogens and tuning immune responses. Science 2001 2.73
20 Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002 2.65
21 Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002 2.55
22 Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 2005 2.51
23 Dendritic cells as vectors for therapy. Cell 2001 2.18
24 Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996 1.99
25 CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 2005 1.78
26 Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000 1.70
27 Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy. Ann Surg 1970 1.68
28 Part I: Vaccines for solid tumours. Lancet Oncol 2004 1.61
29 Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int Rev Immunol 2005 1.57
30 Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012 1.51
31 Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001 1.44
32 Cd4+Cd25+ regulatory T cells and their therapeutic potential. Annu Rev Med 2006 1.39
33 IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest 2013 1.36
34 CD8(+) T-cell immunity to cytomegalovirus. Hum Immunol 2004 1.35
35 Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012 1.33
36 Effective cancer therapy through immunomodulation. Annu Rev Med 2006 1.26
37 Naturally arising CD25+CD4+ regulatory T cells in tumor immunity. Curr Top Microbiol Immunol 2005 1.22
38 Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother Emphasis Tumor Immunol 1996 1.16
39 Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int J Cancer 1999 1.16
40 Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 1998 1.09
41 Melanoma immunology: past, present and future. Curr Opin Oncol 2007 1.07
42 Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res 1990 1.05
43 Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J Immunol 1996 1.05
44 A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer 1996 1.03
45 The use of melanosomal proteins in the immunotherapy of melanoma. J Immunother 1998 0.98
46 pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Med 2016 0.94
47 Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clin Cancer Res 2005 0.93
48 Biomarkers for melanoma. Curr Opin Oncol 2005 0.90
49 Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res 2006 0.88
50 Amino-terminal extended peptide single-chain trimers are potent synthetic agonists for memory human CD8+ T cells. J Immunol 2012 0.87
51 Optimizing dendritic cell-based approaches for cancer immunotherapy. Yale J Biol Med 2014 0.85
52 Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Front Immunol 2015 0.82
53 Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol 2006 0.81
54 Sensitisation of lymphocytes in vitro against human melanoma-associated antigens. Nature 1974 0.80
55 Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines (Basel) 2015 0.80
56 International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res 2004 0.79
57 DC therapy for metastatic melanoma. Cytotherapy 2004 0.78
58 Update: current management issues in malignant melanoma. Melanoma Res 2005 0.75
Next 100